Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alexandra S. Bailey, SuChun Cheng, Eugene D. Kwon, Bradley C. Leibovich, Sabina Signoretti, Janice P. Dutcher, Leonard Joseph Appleman, Jeffrey Alan Sosman, Kim Allyson Margolin, Joseph Clark, Nikhil I. Khushalani, Brendan D. Curti, Marc S. Ernstoff, Allan J. Pantuck, Ulka N. Vaishampayan, Theodore Logan, David F. McDermott, Michael B. Atkins, Cytokine Working Group
Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Mayo Clinic, Brigham and Women's Hospital, Harvard University, St. Luke's-Roosevelt Hospital Center, University of Pittsburgh, Vanderbilt University Medical Center, University of Washington, Loyola University Medical Center, Roswell Park Comprehensive Cancer Center, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, University of California, Los Angeles, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2531889330